eISSN: 1897-4309
ISSN: 1428-2526
Contemporary Oncology/Współczesna Onkologia
Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications
2/2024
vol. 28
 
Share:
Send email
Share:
Original paper

Evaluation of selected circulating cytokines from the IL-6 family – interleukin 6, oncostatin M, and cardiotrophin-1 – in gastro-entero-pancreatic and bronchial neuroendocrine tumours

Janusz Strzelczyk
1
,
Ksenia Janas
1
,
Joanna Katarzyna Strzelczyk
2
,
Elżbieta Chełmecka
3
,
Dariusz Kajdaniuk
4
,
Beata Kos-Kudła
1

  1. Department of Endocrinology and Neuroendocrine Tumors, Department of Pathophysiology and Endocrinology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland
  2. Department of Medical and Molecular Biology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland
  3. Department of Medical Statistics, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia, Katowice, Poland
  4. Department of Pathophysiology, Chair of Pathophysiology and Endocrinology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland
Contemp Oncol (Pozn) 2024; 28 (2): 114–120
DOI: https://doi.org/10.5114/wo.2024.142584
Online publish date: 2024/08/23
Article file
- Evaluation of selected.pdf  [0.11 MB]
Get citation
 
PlumX metrics:
 
1. Kos-Kudła B, Foltyn W, Malczewska A, et al. Update of the diagnostic and therapeutic guidelines for gastro-entero-pancreatic neuroendocrine neoplasms (recommended by the Polish Network of Neuroendocrine Tumours). Endokrynol Pol 2022; 73: 387-454.
2. Pavel M, Öberg K, Falconi M, et al. ESMO Guidelines Committee. Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2020; 31: 844-860.
3. Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol 2017; 3: 1335-1342.
4. Nagtegaal ID, Odze RD, Klimstra D, et al. WHO classification of tumours editorial board. The 2019 WHO classification of tumours of the digestive system. Histopathology 2020; 76: 182-188.
5. Nicholson AG, Tsao MS, Beasley MB, et al. The 2021 WHO classification of lung tumors: impact of advances since 2015. J Thorac Oncol 2022; 17: 362-387.
6. Tsoli M, Koumarianou A, Angelousi A, Kaltsas G. Established and novel circulating biomarkers for diagnostic, predictive and prognostic use. Best Pract Res Clin Endocrinol Metab 2023; 37: 101785.
7. Pavel M, O’Toole D, Costa F, et al. Vienna Consensus Conference participants. ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site. Neuroendocrinology 2016; 103: 172-185.
8. Gibson WE, Gonzalez RS, Cates JMM, Liu E, Shi C. Hepatic micrometastases are associated with poor prognosis in patients with liver metastases from neuroendocrine tumors of the digestive tract. Hum Pathol 2018; 79: 109-115.
9. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.
10. Garbers C, Rose-John S. Dissecting interleukin-6 classic and trans-signaling in inflammation and cancer. Methods Mol Biol 2023; 2691: 207-224.
11. Thongchot S, Vidoni C, Ferraresi A, et al. Cancer-associated fibroblast-derived il-6 determines unfavorable prognosis in cholangiocarcinoma by affecting autophagy-associated chemoresponse. Cancers (Basel) 2021; 13: 2134.
12. Yang B, Zhang J, Wang J, et al. CSNK2A1-mediated MAX phosphorylation upregulates HMGB1 and IL-6 expression in cholangiocarcinoma progression. Hepatol Commun 2023; 7: e00144.
13. Soler MF, Abaurrea A, Azcoaga P, Araujo AM, Caffarel MM. New perspectives in cancer immunotherapy: targeting IL-6 cytokine family. J Immunother Cancer 2023; 11: e007530.
14. Jones SA, Jenkins BJ. Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer. Nat Rev Immunol 2018; 18: 773-789.
15. Hermanns HM. Oncostatin M and interleukin-31: cytokines, receptors, signal transduction and physiology. Cytokine Growth Factor Rev 2015; 26: 545-558.
16. Lee BY, Hogg EKJ, Below CR, et al. Heterocellular OSM-OSMR signalling reprograms fibroblasts to promote pancreatic cancer growth and metastasis. Nat Commun 2021; 12: 7336.
17. Yu Z, Li Z, Wang C, et al. Oncostatin M receptor, positively regulated by SP1, promotes gastric cancer growth and metastasis upon treatment with Oncostatin M. Gastric Cancer 2019; 22: 955-966.
18. Dinca SC, Greiner D, Weidenfeld K, Bond L, Barkan D, Jorcyk CL. Novel mechanism for OSM-promoted extracellular matrix remodeling in breast cancer: LOXL2 upregulation and subsequent ECM alignment. Breast Cancer Res 2021; 23: 56.
19. Chen M, Ren R, Lin W, Xiang L, Zhao Z, Shao B. Exploring the oncostatin M (OSM) feed-forward signaling of glioblastoma via STAT3 in pan-cancer analysis. Cancer Cell Int 2021; 21: 565.
20. López-Yoldi M, Moreno-Aliaga MJ, Bustos M. Cardiotrophin-1: a multifaceted cytokine. Cytokine Growth Factor Rev 2015; 26: 523-532.
21. Konii H, Sato K, Kikuchi S, et al. Stimulatory effects of cardiotrophin 1 on atherosclerosis. Hypertension 2013; 62: 942-950.
22. López-Andrés N, Calvier L, Labat C, et al. Absence of cardiotrophin 1 is associated with decreased age-dependent arterial stiffness and increased longevity in mice. Hypertension 2013; 61: 120-129.
23. Miteva K, Baptista D, Montecucco F, et al. Cardiotrophin-1 deficiency abrogates atherosclerosis progression. Sci Rep 2020; 10: 5791.
24. Akkoc Y, Dalci K, Karakas HE, et al. Tumor-derived CTF1 (cardiotrophin 1) is a critical mediator of stroma-assisted and autophagy-dependent breast cancer cell migration, invasion and metastasis. Autophagy 2023; 19: 306-323.
25. Geisler L, Hellberg T, Lambrecht J, et al. Inflammatory cytokines associated with diagnosis, tumor grade and prognosis in patients with neuroendocrine tumors. J Clin Med 2022; 11: 6191.
26. Pereira SS, Pereira R, Santos AP, et al. Higher IL-6 peri-tumoural expression is associated with gastro-intestinal neuroendocrine tumour progression. Pathology 2019; 51: 593-599.
27. Chen MF, Chen PT, Lu MS, Lin PY, Chen WC, Lee KD. IL-6 expression predicts treatment response and outcome in squamous cell carcinoma of the esophagus. Mol Cancer 2013; 12: 26.
28. Guo Y, Xu F, Lu T, Duan Z, Zhang Z. Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat Rev 2012; 38: 904-910.
29. Kumari N, Dwarakanath BS, Das A, Bhatt AN. Role of interleukin-6 in cancer progression and therapeutic resistance. Tumour Biol 2016; 37: 11553-11572.
30. Magidey-Klein K, Cooper TJ, Kveler K, et al. IL-6 contributes to metastatic switch via the differentiation of monocytic-dendritic progenitors into prometastatic immune cells. J Immunother Cancer 2021; 9: e002856.
31. Abaurrea A, Araujo AM, Caffarel MM. The role of the IL-6 cytokine family in epithelial-mesenchymal plasticity in cancer progression. Int J Mol Sci 2021; 22: 8334.
32. Lamano JB, Lamano JB, Li YD. et al. Glioblastoma-derived IL6 induces immunosuppressive peripheral myeloid cell PD-L1 and promotes tumor growth. Clin Cancer Res 2019; 25(: 3643-3657.
33. Zhang W, Liu Y, Yan Z, et al, R. IL-6 promotes PD-L1 expression in monocytes and macrophages by decreasing protein tyrosine phosphatase receptor type O expression in human hepatocellular carcinoma. J Immunother Cancer 2020; 8: e000285.
34. Kuo IY, Yang YE, Yang PS, et al. Converged Rab37/IL-6 trafficking and STAT3/PD-1 transcription axes elicit an immunosuppressive lung tumor microenvironment. Theranostics 2021; 11: 7029-7044.
35. Ware MB, Phillips M, McQuinn C, et al. Dual IL-6 and CTLA-4 blockade regresses pancreatic tumors in a T cell- and CXCR3-dependent manner. JCI Insight 2023; 8: e155006.
36. Araujo AM, Abaurrea A, Azcoaga P, et al. Stromal oncostatin M cytokine promotes breast cancer progression by reprogramming the tumor microenvironment. J Clin Invest 2022; 132: e165107.
37. Jahani-Asl A, Yin H, Soleimani VD, et al. Control of glioblastoma tumorigenesis by feed-forward cytokine signaling. Nat Neurosci 2016; 19: 798-806.
38. Caffarel MM, Coleman N. Oncostatin M receptor is a novel therapeutic target in cervical squamous cell carcinoma. J Pathol 2014; 232: 386-390.
39. Fossey SL, Bear MD, Kisseberth WC, Pennell M, London CA. Oncostatin M promotes STAT3 activation, VEGF production, and invasion in osteosarcoma cell lines. BMC Cancer 2011; 11: 125.
40. Hara T, Chanoch-Myers R, Mathewson ND, et al. Interactions between cancer cells and immune cells drive transitions to mesenchymal-like states in glioblastoma. Cancer Cell 2021; 39: 779-792.e11.
41. Geethadevi A, Nair A, Parashar D, et al. Oncostatin M receptor-targeted antibodies suppress STAT3 signaling and inhibit ovarian cancer growth. Cancer Res 2021; 81: 5336-5352.
42. Zaporowska-Stachowiak I, Springer M, Stachowiak K, et al. Interleukin-6 family of cytokines in cancers. J Interferon Cytokine Res 2024; 44: 45-59.
43. Scoles DR, Xu X, Wang H, et al. Liver X receptor agonist inhibits proliferation of ovarian carcinoma cells stimulated by oxidized low density lipoprotein. Gynecol Oncol 2010; 116: 109-116.
44. Bustos M, Dubrot J, Martinez-Anso E, et al. Cardiotrophin-1 determines liver engraftment of syngenic colon carcinoma cells through an immune system-mediated mechanism. Oncoimmunology 2012; 1: 1527-1536.
45. Cives M, Pelle’ E, Quaresmini D, Rizzo FM, Tucci M, Silvestris F. The tumor microenvironment in neuroendocrine tumors: biology and therapeutic implications. Neuroendocrinology 2019; 109: 83-99.
46. Zhang WH, Wang WQ, Gao HL, Yu XJ, Liu L. The tumor immune microenvironment in gastroenteropancreatic neuroendocrine neoplasms. Biochim Biophys Acta Rev Cancer 2019; 1872: 188311.
47. Xue J, Bai J, Long Q, et al. TCF-3-mediated transcription of lncRNA HNF1A-AS1 targeting oncostatin M expression inhibits epithelial-mesenchymal transition via TGFβ signaling in gastroenteropancreatic neuroendocrine neoplasms. Aging (Albany NY) 2021; 13: 14065-14077.
Copyright: © 2024 Termedia Sp. z o. o. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
FEATURED PRODUCTS
BOOKS
• Genetyka i leczenie chłoniaka rozlanego z dużych komórek B (DLBCL)
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.